» Articles » PMID: 33738282

Could Extracellular Vesicles Contribute to Generation or Awakening of "Sleepy" Metastatic Niches?

Overview
Specialty Cell Biology
Date 2021 Mar 19
PMID 33738282
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Pre-metastatic niches provide favorable conditions for tumor cells to disseminate, home to and grow in otherwise unfamiliar and distal microenvironments. Tumor-derived extracellular vesicles are now recognized as carriers of key messengers secreted by primary tumors, signals that induce the formation of pre-metastatic niches. Recent evidence suggests that tumor cells can disseminate from the very earliest stages of primary tumor development. However, once they reach distal sites, tumor cells can persist in a dormant state for long periods of time until their growth is reactivated and they produce metastatic lesions. In this new scenario, the question arises as to whether extracellular vesicles could influence the formation of these metastatic niches with dormant tumor cells? (here defined as "sleepy niches"). If so, what are the molecular mechanisms involved? In this perspective-review article, we discuss the possible influence of extracellular vesicles in early metastatic dissemination and whether they might play a role in tumor cell dormancy. In addition, we comment whether extracellular vesicle-mediated signals may be involved in tumor cell awakening, considering the possibility that extracellular vesicles might serve as biomarkers to detect early metastasis and/or minimal residual disease (MRD) monitoring.

Citing Articles

Biogenesis and functional implications of extracellular vesicles in cancer metastasis.

Sekar S, Srikanth S, Mukherjee A, Gopalakrishnan A, Wanjari U, Vellingiri B Clin Transl Oncol. 2024; .

PMID: 39704958 DOI: 10.1007/s12094-024-03815-8.


Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers.

Shi J, Shen Y, Zhang J Cancer Drug Resist. 2024; 7:38.

PMID: 39403606 PMC: 11472704. DOI: 10.20517/cdr.2024.81.


Dormancy and awakening of cancer cells: the extracellular vesicle-mediated cross-talk between Dr. Jekill and Mr. Hyde.

DAntonio C, Liguori G Front Immunol. 2024; 15:1441914.

PMID: 39301024 PMC: 11410588. DOI: 10.3389/fimmu.2024.1441914.


Cancer treatments as paradoxical catalysts of tumor awakening in the lung.

Nicolas E, Kosmider B, Cukierman E, Borghaei H, Golemis E, Borriello L Cancer Metastasis Rev. 2024; 43(4):1165-1183.

PMID: 38963567 PMC: 11554904. DOI: 10.1007/s10555-024-10196-5.


BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells.

Alashkar Alhamwe B, Ponath V, Alhamdan F, Dorsam B, Landwehr C, Linder M Cell Mol Immunol. 2024; 21(8):918-931.

PMID: 38942797 PMC: 11291976. DOI: 10.1038/s41423-024-01195-1.


References
1.
Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki J . Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014; 124(25):3748-57. PMC: 4263983. DOI: 10.1182/blood-2014-05-576116. View

2.
Risson E, Nobre A, Maguer-Satta V, Aguirre-Ghiso J . The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2021; 1(7):672-680. PMC: 7929485. DOI: 10.1038/s43018-020-0088-5. View

3.
Zhang Y, Wang S, Dudley A . Models and molecular mechanisms of blood vessel co-option by cancer cells. Angiogenesis. 2019; 23(1):17-25. PMC: 7018564. DOI: 10.1007/s10456-019-09684-y. View

4.
Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

5.
Vallabhaneni K, Penfornis P, Xing F, Hassler Y, Adams K, Mo Y . Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway. Oncotarget. 2018; 8(66):109861-109876. PMC: 5746349. DOI: 10.18632/oncotarget.22371. View